Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Zawya44m
Cement producer Titan America raises $384mln in US IPO
Titan America has raised $384 million after pricing its U.S. initial public offering at $16 per share, within its targeted ...